Lundbeck Comes to Boston: A Chance to Usher Brain Research Forward
From anesthesia to the polio vaccine, cortisone to catheters, EKGs to MRIs, many discoveries that have changed medicine forever began in Boston, Massachusetts. With its amazing concentration of world class universities, research institutions and biopharmaceutical companies, few plots of earth possess the density of scientific talent, creativity, and ambition as Boston’s 90 square miles.
At Lundbeck, we want to help usher forward Boston’s next generation of innovation.
This week, in partnership with MassBio, Lundbeck will convene nearly 150 representatives of leading Boston-area biotechnology firms, small pharmaceutical companies, and academic research centers, all of whom possess chemical entities or technologies that offer exciting possibilities for improving treatment of psychiatric and neurological illnesses like Alzheimer’s disease, depression, Parkinson’s disease, and schizophrenia. Over the course of two days, R&D leaders from our headquarters in Copenhagen will have an opportunity to share more about our company and the qualities that make us unique (our 70+ year history in brain research, our singular focus on neuroscience, and the work of our largest shareholder, the Lundbeck Foundation), as well as discuss potential partnerships to help these organizations take their pioneering research forward.
As the number of people suffering from brain disorders worldwide grows – hundreds of millions of individuals and counting – the need to achieve new generations of breakthroughs has never been more urgent. We know that to get radically different results, we need to pursue radically different theories. Partnerships that marry organizations focused on early-stage research with the expertise, resources, and infrastructure of companies like Lundbeck are critical to our success in dealing with this public health crisis.
At Lundbeck, partnering with innovative biotech companies and academic research centers has long been an essential part of our R&D philosophy. As an example, just two months ago, we announced a new milestone reached in our work with Ossianix, a biotech company which is utilizing the unique properties of shark antibodies that date back more than 400 million years to potentially deliver high concentrations of therapies across the blood-brain barrier to treat diseases like Alzheimer’s and schizophrenia. I know there are countless more ideas in existence today that, supplied with necessary resources, could have amazing results.
Over these next two days, I am glad that Lundbeck will get to meet so many brilliant scientists and convey our successful R&D track record and passion for beating brain disorders. As Boston’s rich research history can certainly attest, no matter how challenging the disease, breakthroughs are never as far away as they seem – especially if the right people are brought together to incubate them.